Close Menu

NEW YORK (GenomeWeb) – The US Food and Drug Administration's authorization last week of a 468-gene tumor profiling test puts into play several regulatory strategies that the agency has been mulling for some time, but it remains to be seen if other cancer centers and diagnostic companies with similar cancer panels will be willing to pursue the new pathway.

Get the full story with
360Dx Premium

Only $95 for the
first 90 days*

360Dx Premium gives you:
✔ Full site access
✔ Interest-based email alerts
✔ Access to archives

Never miss another important industry story.

Try 360Dx Premium now.

You may already have institutional access!

Check if I qualify.

Already a 360Dx or GenomeWeb Premium member?
Login Now.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.